Related Experiment Video
Updated: Aug 14, 2026

5/6 Nephrectomy Using Sharp Bipolectomy Via Midline Laparotomy in Rats
Published on: April 4, 2025
Uncertainty in the treatment of anemia in chronic kidney disease
Marc A Pfeffer1, Scott D Solomon, Ajay K Singh
1Department of Medicine, Brigham and Women's Hospital, Boston, Massachusetts, USA.
Abstract:
The practice of medicine requires that the assimilation of today's best available data be directed toward individual patient-care decisions. In the absence of definitive data, surrogate measures are adopted to anticipate how therapeutic strategies would influence clinical outcomes and prognosis. Unfortunately, randomized controlled clinical trials (RCTs) have not always found these estimates of outcome to be reliable. Anemia is a clear marker of adverse prognosis, which can be modified by erythropoietic stimulating proteins (ESP). At present, there is sufficient uncertainty regarding the risks and benefits of ESP treatment in patients with chronic kidney disease and anemia to warrant major RCTs. This article reviews the rationale and design features for these trials.
Related Concept Videos
Chronic Kidney Disease III: Interprofessional Care
Chronic Kidney Disease II: Clinical Manifestations
Chronic Kidney Disease IV: Nursing Management
Drug Dosing in Renal Diseases: Dose Adjustments Based on Drug Clearance and Elimination Rate Constant
Chronic Kidney Disease I: Introduction
Acute Kidney Injury V: Interprofessional Care